Free Trial

Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) Lock-Up Period Will Expire on July 7th

Zhengye Biotechnology logo with Medical background

Zhengye Biotechnology's (NASDAQ:ZYBT - Get Free Report) lock-up period is set to expire on Monday, July 7th. Zhengye Biotechnology had issued 1,500,000 shares in its initial public offering on January 7th. The total size of the offering was $6,000,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Zhengye Biotechnology Stock Up 2.2%

Shares of NASDAQ ZYBT traded up $0.13 during mid-day trading on Thursday, hitting $6.05. 124,393 shares of the company traded hands, compared to its average volume of 374,983. Zhengye Biotechnology has a 1 year low of $3.50 and a 1 year high of $14.30. The business's 50 day moving average is $8.58.

Zhengye Biotechnology Company Profile

(Get Free Report)

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

Featured Stories

Should You Invest $1,000 in Zhengye Biotechnology Right Now?

Before you consider Zhengye Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zhengye Biotechnology wasn't on the list.

While Zhengye Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Why Drone Stocks Are Skyrocketing Right Now!
Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters
This Strategy Beat the S&P—And Most Investors Ignore It

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines